These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 30141019)

  • 1. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
    Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
    Front Immunol; 2021; 12():690105. PubMed ID: 34054879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating Tumor-Associated Tertiary Lymphoid Structures in Murine Lung Adenocarcinoma.
    Connolly KA; Nader M; Joshi N
    Methods Mol Biol; 2018; 1845():259-273. PubMed ID: 30141018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.
    Rodriguez AB; Peske JD; Engelhard VH
    Methods Mol Biol; 2018; 1845():241-257. PubMed ID: 30141017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.
    Engelhard VH; Rodriguez AB; Mauldin IS; Woods AN; Peske JD; Slingluff CL
    J Immunol; 2018 Jan; 200(2):432-442. PubMed ID: 29311385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tertiary lymphoid structures in the era of cancer immunotherapy.
    Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
    Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
    Fridman WH; Petitprez F; Sautes-Fridman C
    Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
    [No Abstract]   [Full Text] [Related]  

  • 9. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tertiary lymphoid structures in cancer: maturation and induction.
    Chen Y; Wu Y; Yan G; Zhang G
    Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer.
    Jones E; Gallimore A; Ager A
    Methods Mol Biol; 2018; 1845():99-118. PubMed ID: 30141010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designed Methods for the Sorting of Tertiary Lymphoid Structure-Immune Cell Populations.
    Devi-Marulkar P; Kaplon H; Dieu-Nosjean MC; Lawand M
    Methods Mol Biol; 2018; 1845():189-204. PubMed ID: 30141014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Tools for the Selective Visualization and Quantification of TLS-Immune Cells on Tissue Sections.
    Klein C; Devi-Marulkar P; Dieu-Nosjean MC; Germain C
    Methods Mol Biol; 2018; 1845():47-69. PubMed ID: 30141007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
    Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
    Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
    Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
    Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy.
    Tian W; Wei W; Qin G; Bao X; Tong X; Zhou M; Xue Y; Zhang Y; Shao Q
    Front Immunol; 2024; 15():1403578. PubMed ID: 39076974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy.
    Langouo Fontsa M; Padonou F; Willard-Gallo K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):839-847. PubMed ID: 39007892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.